Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure

Atherosclerosis

Volumn 199, Issue 1, 2008, Pages 215-221

  Kourea, Kallirrhoe ^a   Parissis, John T ^a   Farmakis, Dimitrios ^a   Panou, Fotios ^a   Paraskevaidis, Ioannis ^a   Venetsanou, Koula ^a   Filippatos, Gerasimos ^a   Kremastinos, Dimitrios Th ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anemia; Apoptosis; Endothelial activation; Erythropoietin; Heart failure; Pro inflammatory cytokines

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; FAS LIGAND; FERROUS SULFATE; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; WALKING;

AGED; ANEMIA; ANTIGENS, CD95; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; CYTOKINES; ERYTHROPOIETIN; FAS LIGAND PROTEIN; FEMALE; HEART FAILURE; HEMATINICS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; SOLUBILITY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 45249104659     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.09.039     Document Type: Article

References (33)

1. Mann D., and Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of pro-inflammatory cytokines. Chest 105 (1994) 897-904
2. Adamopoulos S., Parissis J., and Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 3 (2001) 517-526
3. Li Y., Takemura G., Kosai K., et al. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ Res 17 95 (2004) 627-636
4. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
5. Macdugall I.C., and Cooper A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17 Suppl 11 (2002) 39-43
6. Burger D., Lei M., Geoghegan-Morphet N., et al. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 72 (2006) 51-59
7. Feng Q. Beyond eythropoiesis: the anti-inflammatory effects of erythropoietin. Cardiovasc Res 71 (2006) 615-617
8. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
9. Silverberg D.S., Wexler D., Blum B., et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18 (2003) 141-146
10. Mancini D., Katz S., Lang C., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
11. Ponikowski P., Anker S., Szachniewicz J., et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49 (2007) 753-762
12. Henry D., Bowers P., Romano M., and Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 164 (2004) 262-276
13. Cleland J., Sullivan J., Ball S., et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 46 (2005) 155-161
14. Vansteenkiste J. Every 3 weeks dosing with darbepoetin alfa: a new paradigm in anaemia management. Cancer Treat Rev 32 Suppl 2 (2006) S11-S15
15. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. Am J Soc Echocardiogr 2 (1989) 358-368
16. Parsa C., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
17. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelling. Proc Natl Acad Sci USA 100 (2003) 4802-4806
18. Li Y., Takemura G., Okada H., et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 7 (2006) 684-694
19. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
20. Adamopoulos S., Parissis J., and Kremastinos D. Endothelial dysfunction in chronic heart failure: clinical and therapeutic implications. Eur J Int Med 13 (2002) 233-239
21. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1587-1593
22. Ralli S., Horwich T., and Fonarow G. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 150 (2005) 1220-1227
23. Palazzuoli A., Silverberg D., Iovine F., et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152 (2006) e9-e15 1096
24. Mitsuma W., Ito M., Kodama M., et al. Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 344 (2006) 987-994
25. Foley R.N. Myocardial disease, anemia, and erythrocyte-stimulating proteins in chronic kidney disease. Rev Cardiovasc Med 6 Suppl 3 (2005) S27-S34
26. Iversen P.O., Woldbaek P.R., Tønnessen T., and Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 282 (2002) R166-R172
27. Laftah A., Sharma N., Brookes M., et al. Tumour necrosis factor-alpha causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J 397 (2006) 61-67
28. Smith K.J., Bleyer A.J., Little A.J., and Sane D.C. The cardiovascular effects of erythropoietin. Cardiovasc Res 59 (2003) 538-548
29. Tobu M., Iqbal O., Fareed D., et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 10 (2004) 225-232
30. Okuyama M., Yamagouchi S., Nozaki N., et al. Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am J Cardiol 79 (1997) 1698-1701
31. Yamagouchi S., Yamaoka M., Okuyama M., et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol 83 (1999) 1500-1503
32. Nishigaki K., Minatoguchi S., Seishima M., et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 29 (1997) 1214-1220
33. Setsuta K., Seino Y., Ogawa T., et al. Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. Circ J 68 (2004) 747-750